At Eye Clinic London we are extremely excited to announce that we have acquired a new revolutionary device for the treatment of dry eyes due to blepharitis/meibomian gland dysfunction (MGD), the E-Eye. We are the very first ophthalmologist lead clinic to have it in London and we cannot wait to start treating dry eyes.
The E-Eye uses intense regulated pulsed light, or IRPL, which has been designed precisely for treating dry eyes caused by MGD. It is the first and only medical device in the world to do this.
Meibomian gland dysfunction (MGD) is a type of dry eye disease, which is also sometimes called blepharitis. Tears are made up of three layers and in MGD the oil layer within the tears is thinner and not as stable as it should be, this in turn causes an inadequate production of tears and can also be accompanied with excess evaporation of tears.
There are many treatments that offer short term relief for MGD sufferers, which tend to be artificial tear drops which require constant instillation but now we have something that can offer the all-important long term relief, the E-Eye.
The E-Eye device creates polychromatic pulse light using the new IRPL (intense regulated pulsed light) technology. The E-Eye releases a flash of light that is made up of a pulse train, which is flashed on the treatment area (cheekbone and temple area around the eye). Within this treatment area nerve branches are located and these nerve branches are connected to meibomian gland nerves. When these nerve branches are flashed with the E-Eye (IRPL) it causes a stimulatory response within the meibomian glands and they start to resume secretion of the normal oil layer again and symptoms of eye dryness will disappear. Accordingly, it will be effective in 80% of patients affected by dry eye disease.
From a single flash of IRPL it is possible to produce sub-flashes of varying intensities, this offers unparalleled therapeutic potentials, especially with the treatment of MGD, which is impossible with conventional IPL.
The E-Eye emits a ‘cold light’ and it is non-invasive, totally painless and entirely harmless to the eyeball.
The E-Eye is effective in all cases of dry eye disease that is related to MGD. The length of the treatment’s efficacy increases with the number of treatments completed. Effective for 1 week after the first treatment, 2-3 weeks after the second treatment and 6 months to more than 2 years after the third or fourth treatment. We can truly say it is a long term relief of MGD.
Here are a few facts directly from the makers of the E-Eye device:
• No. 1 dry eye solution to treat Meibomian Gland Dysfunction (MGD).
• In 2015, over 35,000 patients have been treated with the E-Eye worldwide!
• 84% efficiency from the first session.
• + 86% satisfaction rate, proven efficiency on mild, medium and severe dry eye.
• 3 clinical studies conducted on over 300 people.
• Up to 18-month relief for the patient.
• More than 100% increase in the break-up time.
• 100% satisfaction amongst users.
If you would like any more information about the E-Eye (IRPL) treatment or to find out when we will be starting to offer this brand new treatment to the UK, please contact us on 0800 197 8808 or firstname.lastname@example.org